Marcos Monteiro-Machado

Dr. Marcos Monteiro-Machado

Universidade Federal do Rio de Janeiro – UFRJ
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2013 in Toxicon
Verified
Journal Article
Closed access
FPFernando Chagas Patrão-Neto
Fernando Chagas Patrão-Neto
MTMarcelo Amorim Tomaz
Marcelo Amorim Tomaz
MSMarcelo Abrahão Strauch
Marcelo Abrahão Strauch
Marcos Monteiro-MachadoMarcos Monteiro-Machado
Marcos Monteiro-Machado
JRJosé Roberto Da Silva Rocha-Junior
José Roberto Da Silva Rocha-Junior
PMPaulo A. Melo
Paulo A. Melo

1 January 2013 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
MSMarcelo Abrahão Strauch
Marcelo Abrahão Strauch
MTMarcelo Amorim Tomaz
Marcelo Amorim Tomaz
Marcos Monteiro-MachadoMarcos Monteiro-Machado
Marcos Monteiro-Machado
HRHilmar Dias Ricardo
Hilmar Dias Ricardo
BCBruno Lemos Cons
Bruno Lemos Cons
PMPaulo A. Melo
Paulo A. Melo

1 August 2014 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
FFFabrício F.A. Fernandes
Fabrício F.A. Fernandes
MTMarcelo A. Tomaz
Marcelo A. Tomaz
CECamila Z. El-Kik
Camila Z. El-Kik
Marcos Monteiro-MachadoMarcos Monteiro-Machado
Marcos Monteiro-Machado
MSMarcelo A. Strauch
Marcelo A. Strauch
PMPAULO A MELO
PAULO A MELO

1 May 2015 in Toxicon
Verified
Journal Article
Closed access
Marcos Monteiro-MachadoMarcos Monteiro-Machado
Marcos Monteiro-Machado
MTMarcelo A. Tomaz
Marcelo A. Tomaz
RFRoberto Fonseca
Roberto Fonseca
MSMarcelo A. Strauch
Marcelo A. Strauch
BCBruno L. Cons
Bruno L. Cons
PMPAULO A MELO
PAULO A MELO

28 January 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MSMarcelo Abrahão Strauch
Marcelo Abrahão Strauch
MTMarcelo Amorim Tomaz
Marcelo Amorim Tomaz
Marcos Monteiro-MachadoMarcos Monteiro-Machado
Marcos Monteiro-Machado
BCBruno Lemos Cons
Bruno Lemos Cons
FPFernando Chagas Patrão-Neto
Fernando Chagas Patrão-Neto
PMPAULO A MELO
PAULO A MELO
It is known that local tissue injuries incurred by snakebites are quickly instilled causing extensive, irreversible, tissue destruction that may include loss of limb function or even amputation. Such injuries are not completely neutralized by the available antivenins, which in general are focused on halting systemic effects. Therefore it is prudent to investigate the potential antiophidic effects of natural and synthetic compounds, perhaps combining them with serum therapy, to potentially attenuate or eliminate the adverse local and systemic effects of snake venom. This study assessed a group of quinones that are widely distributed in nature and constitute an important class of natural products that exhibit a range of biological activities. Of these quinones, lapachol is one of the most important compounds, having been first isolated in 1882 from the bark of Tabebuia avellanedae. It was investigated the ability of lapachol and some new potential active analogues based on the 2-hydroxi-naphthoquinone scaffold to antagonize important activities of Bothrops venoms (Bothrops atrox and Bothrops jararaca) under different experimental protocols in vitro and in vivo. The bioassays used to test the compounds were: procoagulant, phospholipase A2, collagenase and proteolytic activities in vitro, venom-induced hemorrhage, edematogenic, and myotoxic effects in mice. Proteolytic and collagenase activities of Bothrops atrox venom were shown to be inhibited by lapachol and its analogues 3a, 3b, 3c, 3e. The inhibition of these enzymatic activities might help to explain the effects of the analogue 3a in vivo, which decreased skin hemorrhage induced by Bothrops venom. Lapachol and the synthetic analogues 3a and 3b did not inhibit the myotoxic activity induced by Bothrops atrox venom. The negative protective effect of these compounds against the myotoxicity can be partially explained by their lack of ability to effectively inhibit phospholipase A2 venom activity. Bothrops atrox venom also induced edema, which was significantly reduced by the analogue 3a. This research using a natural quinone and some related synthetic quinone compounds has shown that they exhibit antivenom activity; especially the compound 3a. The data from 3a showed a decrease in inflammatory venom effects, presumably those that are metalloproteinase-derived. Its ability to counteract such snake venom activities contributes to the search for improving the management of venomous snakebites.

1 March 2015 in Toxicon
Verified
Journal Article
Closed access
MRM.F. Ribeiro
M.F. Ribeiro
FOFelipe Leite Oliveira
Felipe Leite Oliveira
Marcos Monteiro-MachadoMarcos Monteiro-Machado
Marcos Monteiro-Machado
PCP.F. Cardoso
P.F. Cardoso
VGV.V.C. Guilarducci-Ferraz
V.V.C. Guilarducci-Ferraz
SCS. Calil-Elias
S. Calil-Elias